André C, Holsti C, Svenner A, Sackey H, Oikonomou I, Appelgren M, Johansson A L V, de Boniface J
Department of Surgery, Capio St Göran's Hospital, Stockholm, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
BJS Open. 2021 Jan 8;5(1). doi: 10.1093/bjsopen/zraa013.
Oncoplastic techniques in breast-conserving surgery (BCS) are used increasingly for larger tumours. This large cohort study aimed to assess oncological outcomes after oncoplastic BCS (OPS) versus standard BCS.
Data for all women who had BCS in three centres in Stockholm during 2010-2016 were extracted from the Swedish National Breast Cancer Register. All patients with T2-3 tumours, all those receiving neoadjuvant treatment, and an additional random sample of women with T1 tumours were selected. Medical charts were reviewed for local recurrences and surgical technique according to the Hoffman-Wallwiener classification. Date and cause of death were retrieved from the Swedish Cause of Death Register.
The final cohort of 4178 breast cancers in 4135 patients was categorized into three groups according to surgical technique: 3720 for standard BCS, 243 simple OPS, and 215 complex OPS. Median duration of follow up was 64 (range 24-110) months. Node-positive and large tumours were more common in OPS than in standard BCS (P < 0.001). There were 61 local recurrences: 57 (1.5 per cent), 1 (0.4 per cent) and 3 (1.4 per cent) in the standard BCS, simple OPS and complex OPS groups respectively (P = 0.368). Overall, 297 patients died, with an unadjusted 5-year overall survival rate of 94.7, 93.1 and 92.6 per cent respectively (P = 0.350). Some 102 deaths were from breast cancer, with unadjusted 5-year cancer-specific survival rates of 97.9, 98.3 and 95.0 per cent respectively (P = 0.056).
Oncoplastic BCS is a safe surgical option, even for larger node-positive tumours, with low recurrence and excellent survival rates.
保乳手术(BCS)中的肿瘤整形技术越来越多地用于治疗较大的肿瘤。这项大型队列研究旨在评估肿瘤整形保乳手术(OPS)与标准保乳手术的肿瘤学结局。
从瑞典国家乳腺癌登记处提取了2010年至2016年期间在斯德哥尔摩三个中心接受保乳手术的所有女性的数据。选取了所有T2-3期肿瘤患者、所有接受新辅助治疗的患者以及另外一组T1期肿瘤女性的随机样本。根据霍夫曼-瓦尔维纳分类法对病历进行了局部复发和手术技术方面的审查。从瑞典死亡原因登记处获取了死亡日期和原因。
4135例患者中的4178例乳腺癌最终队列根据手术技术分为三组:标准保乳手术组3720例、简单肿瘤整形保乳手术组243例、复杂肿瘤整形保乳手术组215例。中位随访时间为64(范围24-110)个月。肿瘤整形保乳手术组中淋巴结阳性和大肿瘤比标准保乳手术组更常见(P<0.001)。共有61例局部复发:标准保乳手术组57例(1.5%)、简单肿瘤整形保乳手术组1例(0.4%)、复杂肿瘤整形保乳手术组3例(1.4%)(P=0.368)。总体而言,297例患者死亡,未经调整的5年总生存率分别为94.7%、93.1%和92.6%(P=0.350)。约102例死亡为乳腺癌所致,未经调整的5年癌症特异性生存率分别为97.9%、98.3%和95.0%(P=0.056)。
肿瘤整形保乳手术是一种安全的手术选择,即使对于较大的淋巴结阳性肿瘤也是如此,复发率低且生存率高。